Loading
精華生醫 Stock: price and insider trades · Taiwan
TW·Mcap NT$1.6B
精華生醫: what insiders have been doing
Only a handful of insider records exist for 精華生醫, the last one from 7 October 2026, too few to describe a trend. Source: insider filings from TWSE / TPEx (MOPS). Past trades are no guide to future returns.
Insider Decl.
1
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
Fundamental score
Ranked 13,262 of 24,148 companies
48.7
score / 100
Value38
Quality59
FCF yld-15%
Earn yld4.6%
EV/EBITDA13.6x
ROE8.8%
Gross mgn30%
Net mgn14%
Debt/EBITDA1.7x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
NT$55
Analyst consensus
Income statement
RevenueNT$538.6M
Gross profitNT$163.8M30% margin
EBITDANT$136M25% margin
Net incomeNT$75.3M10.4% margin
Valuation
PER (trailing)29.5x
P/Book2.1x
Balance sheet & cash
Market capNT$1.6B
Total debtNT$231.1M
Free Cash Flow-NT$236.8M
Debt / Equity29%
Profitability & ownership
ROE8.8%
ROA4.1%
Last declaration on 7 October 2026
About 精華生醫
精華生醫 is a company listed on the XTAI market, specializing in the biotechnology sector. It focuses on developing innovative solutions for the healthcare industry.